The pathogenesis of Parkinson’s disease is mainly due to a decrease in dopamine synthesis in the brain and a disruption of the balance between the cholinergic and dopamine systems, resulting in symptoms such as hyperkinesia, tonicity, and tremor. Therefore, the current drugs are mainly supplemental dopamine synthesis materials and anticholinergic drugs. They can be broadly divided into the following categories: 1) anticholinergic drugs, including Antan (i.e., benzhexol), kemaline, scopolamine, etc.; 2) dopamine replacement drugs, i.e., levodopa. Due to the large dose and side effects of levodopa alone, the compound of levodopa is now used, i.e. Medopa (containing levodopa and benserazide, with three dosage forms: standard tablets, extended-release tablets and diffusion type) and Xanax (containing levodopa and carbidopa, with three dosage forms: standard tablets, controlled-release tablets and water-soluble tablets). Now there is a new compound levodopa called Stalevo, consisting of levodopa, carbidopa and entocapone; 3, dopamine receptor agonists There are bromocriptine, pergolide (Xie Liang Xing), dihydroergot cryptine (Crepa), piribedil (Tesudal), pramipexole, ropinirole, ergocalciferol, ergometrine, capsaicin, apomorphine, etc.; 4, monoamine oxidase B inhibitors, that is, Silegiline (Sanguinil, Midolpir) and Rasegiline; 5, catecholamine – oxygen – methyltransferase inhibitors, i.e., tolcapone (A is the beauty) and entocapone (Kodan); 6, amantadine; 7, other drugs still under investigation.